

FOI 2808

23rd December 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

BREAST CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2024 to the end of September 2024, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	
1.2 Alpelisib (Piqray)	
1.3 Elacestrant (Orserdu)	
1.4 Fulvestrant (fulvestrant or Faslodex)	
1.5 Inavolisib (Inaqovi)	
1.6 Palbociclib (Ibrance)	
1.7 Ribociclib (Kisqali)	
1.8 Capivasertib (Truqap)	

Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of July 2024 to the end of September 2024, or latest 3-month period for which data are available?

Number patients treated

Q3. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of July 2024 to the end of Sep 2024, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
3.1 Curative	

3.2 Palliative
3.3 Not known / stated

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of July 2024 to the end of Sep 2024, or latest 3-month period available?

Name of combination or monotherapy
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)

Number patients treated

Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of July 2024 to the end of Sep 2024?

Type of breast cancer
5.1 all types of breast cancer
5.2 adjuvant treatment for early breast cancer
5.3 locally advanced or metastatic breast cancer

Number patients treated

HER2+VE BREAST CANCER

Q6. How many patients were treated in total with the following products in the 3 months between 1st July 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine
6.1 Pertuzumab (Perjeta)
6.2 Pertuzumab with Trastuzumab (Phesgo)
6.3 Trastuzumab (Herceptin, Herzuma, Ontruzant, Trazimera, Zercepac, trastuzumab)
6.4 Trastuzumab Deruxtecan (EnHertu)
6.5 Trastuzumab Emtansine (Kadcyla)
6.6 Tucatinib (Tukysa)

Number patients treated



Q7. How many patients received trastuzumab emtansine (Kadcyla) with the following treatment intent in the 3 months between the start of July 2024 to the end of Sep 2024, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
7.1 Curative	
7.2 Palliative	
7.3 Not known / stated	

OVARIAN CANCER and ENDOMETRIAL CANCER

Q8. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st July 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
8.1 Niraparib (Zejula)	
8.2 Rucaparib (Rubraca)	
8.3 Olaparib (Lynparza)	

Q9. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between 1st July 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
9.1 Olaparib in total	
9.2 Olaparib monotherapy	
9.3 Olaparib + bevacizumab in combination	
9.4 Bevacizumab total	
9.5 Bevacizumab monotherapy	
9.6 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin	

Q10. How many patients were treated for Endometrial Cancer, with the following medicines in the 3 months between 1st July 2024 and 30th September 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
10.1 Dostarlimab (Jemperli)	
10.2 Pembrolizumab (Keytruda)	
10.3 Lenvatinib (Lenvima)	

Q11. How many patients were treated for Endometrial Cancer, with the following medicines as monotherapy or in combination, in the 3 months between 1st July 2024 and 30th September 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
11.1 Dostarlimab monotherapy	
11.2 Dostarlimab in combination with Chemotherapy	
11.3 Pembrolizumab monotherapy	
11.4 Pembrolizumab + Lenvatinib in combination	
11.5 Lenvatinib monotherapy	

Response:

Unfortunately we are unable to provide the information you have requested as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. It has been estimated that it would take more than 18 hours to locate and retrieve the requested information. In order to obtain the information would require a manual trawl, would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Email: Foi.Team@Southerntrust.hscni.net